(June 25, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today the completion of its public offering of $600 million aggregate principal amount of 5.45 percent Senior Notes due June 15, 2014, under the Company's existing shelf registration statement. Boston Scientific plans to use the proceeds to repay commercial paper borrowings and for other general corporate purposes.

The joint bookrunners for the offering were Banc of America Securities LLC, Deutsche Bank Securities Inc. and JPMorgan.

Nothing herein shall constitute an offer to sell or the solicitation of an offer buy, nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to or qualification under the securities laws of any such state or jurisdiction. The offerings are being made by means of a prospectus and related prospectus supplements only, copies of which or information concerning this offering may be obtained by calling Banc of America Securities LLC at (704) 386-9690, Deutsche Bank Securities Inc. at (212) 250-6801, or J.P. Morgan Securities, Inc. at (212) 834-4533.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.

This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward looking statements and may be adversely affected by, among other things, risks associated with capital markets, new product development and commercialization, clinical trials, intellectual property, regulatory approvals, competitive offerings, integration of acquired companies, the Company's overall business strategy, and other factors described in the Company's filings with the Securities and Exchange Commission.